This article is general information, not medical advice. Dose decisions are made by your prescriber, not by converting mg numbers yourself.
Quick answer: the 25 mg oral semaglutide pill (the Wegovy pill) and the 2.4 mg injection are measured on different scales, so you can't read the mg numbers as a strength comparison. Only around 1% of the swallowed tablet reaches your bloodstream, which is why it needs a much larger mg number. There's no formula for converting one to the other, but the UK and US labels do pair the two top doses: they describe moving from the 2.4 mg injection to the 25 mg tablet, or back, without starting again from the lowest step. Your prescriber decides any switch. At its top dose the pill performed comparably to the injection in the OASIS 4 trial, about 14% weight loss at 64 weeks.
The problem
Questions like these come up on Reddit, Mumsnet, and in private clinic WhatsApp groups:
"I'm on the Wegovy pill at 25mg and want to switch to the injection. The nurse said 2.4mg. Isn't that a huge drop?"
Or:
"The oral semaglutide is 14mg but the injection is only 2.4mg. Aren't I getting way more medicine with the pill?"
No. The mg numbers on the pill and the injection are not measuring the same thing.
The confusion comes from a single fact: the dose units mean different things depending on how you take the drug.
The core issue: bioavailability
Bioavailability is how much of the drug actually gets into your bloodstream.
The injection
- You inject into the fat just under the skin
- Almost all of it reaches your bloodstream
- So a 0.5 mg injection is close to 0.5 mg getting to work in your body
The oral pill
- You swallow it
- It has to survive stomach acid and get absorbed through the gut lining
- Only around 1% of oral semaglutide makes it into your bloodstream (Rybelsus SmPC)
That is why the tablet is measured in far bigger mg numbers than the injection. Rybelsus goes up to 14 mg and the Wegovy weight-loss pill is 25 mg, while the injections top out at 2.4 mg. Bigger number, but most of it never reaches your blood. The mg on the box is what you swallow, not what you absorb.
Why there's no conversion table
Here is where a lot of online advice goes wrong. People take that "1% bioavailability" fact and try to build an mg-to-mg conversion out of it, as if you could multiply your injection dose by some number and land on the matching pill dose. You can't, and you shouldn't.
No regulator publishes a conversion formula between the oral and injectable forms. The UK labels say the effect of switching between semaglutide tablets and the injection "cannot easily be predicted", because absorption from the tablet varies more from person to person (UK SmPC, section 4.2). Bioavailability is an average, and the way a drug behaves in your body doesn't reduce to a tidy multiplier.
Dosing is clinical, not arithmetic. You don't carry your old dose across on a calculator. If you previously saw a neat "5 to 6x" or "3.5x stronger" rule of thumb here, we've removed it, because it was inventing numbers that don't hold up.
What the labels say about switching
What the labels give instead of a formula is one switch in each direction, at the top doses. Between them, the UK labels for Wegovy tablets and the Wegovy injection, and the US label that covers both, say that people on the 2.4 mg weekly injection can move to the 25 mg daily tablet, starting a week after their last injection, and that people on the 25 mg tablet can move to the 2.4 mg injection, starting the day after their last tablet (UK tablets SmPC; UK injection SmPC; US prescribing information, section 2.5). That's a move straight across, not a fresh start from the lowest step. The US label adds that if the 25 mg tablet didn't agree with someone, their prescriber can consider the 1.7 mg injection instead.
The labels don't give a switching dose for anyone on a lower step, and they're written for prescribers, not as instructions for you. Whether you switch, when, and at what dose is your prescriber's decision, based on how you're getting on.
Does the pill work as well?
This is the question underneath all the mg worry: if the injection delivers more to my blood, is the pill just weaker? At the top dose, no.
In the OASIS 4 trial, oral semaglutide 25 mg produced about 14% weight loss at 64 weeks, which the researchers found comparable to the 2.4 mg weekly injection (OASIS 4, ACC). So even though the pill needs a much larger mg number and only around 1% is absorbed, the dose was set so the end result matches the injection. That is exactly why you can't read the raw mg figures as a strength comparison.
Worth separating from this: the lower-dose Rybelsus tablets (3, 7, 14 mg) are licensed for type 2 diabetes and do produce less weight loss than the high-dose pill. That is a different product at a different dose, not proof that "pills are weaker."
Why the confusion happens
Reason 1: same brand name, different numbers
Novo Nordisk uses the Wegovy name for both the injection and the pill, but the doses are on completely different scales. It looks like they should line up. They don't.
Reason 2: people assume "mg is mg"
For most medicines, 10 mg means 10 mg of active ingredient reaching you. But when the route of administration changes, how much actually gets absorbed changes with it.
Reason 3: dose changes don't always get explained
Some clinics just give the new number, say 2.4 mg after a 25 mg pill, without explaining why it's so much smaller. That silence is where the panic starts.
The absorption enhancer
Here's the detail that makes an oral GLP-1 possible at all: oral semaglutide tablets contain an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, usually shortened to SNAC.
What it does is create a small, local, temporary window in the stomach lining that lets semaglutide cross into the blood before the tablet moves on. Without something like SNAC, a peptide this size would be absorbed almost not at all, and an oral version simply wouldn't work. Even with it, bioavailability sits at roughly 1%, which is why the tablet still needs a large mg dose and strict timing on an empty stomach (Rybelsus SmPC).
What you need to know
- Don't compare the mg numbers directly. A 25 mg pill is not "ten times" a 2.4 mg injection.
- There's no conversion formula. For semaglutide, the labels pair the 2.4 mg injection with the 25 mg tablet for people switching at the top doses, and give no switching dose for lower steps. Your prescriber decides any switch and its dose.
- At the top dose the pill works about as well as the injection, per OASIS 4. The weaker option is low-dose Rybelsus, which is a different product for diabetes.
- Your prescriber decides the dose. If they change your prescription without explaining the new number, ask them to talk you through it.
The FAQ we hear
Q: "I'm on a 1.0mg injection and want to try the oral version. What dose do I ask for?"
A: You don't ask for a particular dose, and you don't pick it off a conversion chart. The UK and US labels only give a switching dose for people on the 2.4 mg injection, who can move to the 25 mg tablet. For a 1.0 mg injection there's no labelled switching dose, so whether to switch, and the dose to start on, is your prescriber's decision.
Q: "The pill is 25mg and the injection is 2.4mg. Am I getting ten times the medicine?"
A: No. Only about 1% of the tablet is absorbed. The big mg number offsets the low absorption, which is why the 25 mg pill ends up roughly as effective as the 2.4 mg injection. Those are also the two doses the labels pair for people switching between them.
Q: "Does this mean the pill is less effective than the injection?"
A: Not at the top dose. OASIS 4 found oral semaglutide 25 mg comparable to the 2.4 mg injection. The lower-dose Rybelsus tablets do less, but that's a different dose for a different use.
A note on what's next
The oral GLP-1 field is moving fast. Eli Lilly's oral drug, orforglipron, is a once-daily pill sold as Foundayo. The FDA approved it in the US in April 2026 (Drugs.com), and the MHRA licensed it in the UK on 10 August 2026, where it is a private prescription (GOV.UK). Its doses run from 0.8 mg to 17.2 mg, and like every oral GLP-1 those numbers do not line up with injection doses either. We cover it in our Foundayo explainer. The Wegovy pill, meanwhile, was approved by the MHRA in June 2026 and is available privately in the UK (GOV.UK).
For now: if you're switching between formats, ask your prescriber how the dose changes. Don't do the maths yourself. The mg numbers are different, but the medicine is the same.
View sources (8)
- OASIS 4: oral semaglutide 25 mg weight loss comparable to the injection, American College of Cardiology
- Rybelsus (oral semaglutide) Summary of Product Characteristics, electronic medicines compendium
- Wegovy 25 mg tablets, Summary of Product Characteristics, section 4.2, electronic medicines compendium (revised June 2026)
- Wegovy FlexTouch (semaglutide injection), Summary of Product Characteristics, section 4.2, electronic medicines compendium (revised September 2026)
- Wegovy (semaglutide) injection and tablets, US prescribing information, section 2.5, Novo Nordisk (revised June 2026)
- First GLP-1 tablet for weight loss approved in the UK, GOV.UK
- Foundayo (orforglipron) FDA approval history, Drugs.com
- UK first in Europe to authorise orforglipron for weight management and type 2 diabetes, GOV.UK, 10 August 2026



